Megan Brooks July 21, 2023 Treatment with an experimental oral tau aggregation inhibitor, hydromethylthionine mesylate (HMTM), led to a statistically significant reduction in an established biomarker of neurodegeneration in Alzheimer’s disease (AD) in the LUCIDITY phase 3 trial. Blood concentrations of neurofilament light chain (NfL) showed a 93% reduction in change over 12 months in participants receiving...